Shopping Cart
Remove All
Your shopping cart is currently empty
Stapokibart
(Synonyms: CM310, CM 310) Copy Product Info
🥰Excellent
Synonyms: CM310, CM 310
Catalog No. T81098 Copy Product Info
🥰Excellent
Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα, blocking IL-4Rα-mediated signaling. It is used in studies of atopic dermatitis.
Cas No. 2734715-10-5
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | In Stock | In Stock | |
| 5 mg | $619 | - | In Stock | |
| 10 mg | $993 | - | In Stock | |
| 25 mg | $1,470 | - | In Stock | |
| 50 mg | $1,980 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:96.09% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα, blocking IL-4Rα-mediated signaling. It is used in studies of atopic dermatitis. |
| In vitro | Stapokibart showed high affinity binding to IL-4Rα in human, cynomophage monkey and rat with equilibrium dissociation constant (KD) values of 0.25, 1.5 and 2.75 nM and IC50 values of 0.40 nM, respectively. In HEK293-STAT6 reporter cells, Stapokibart showed concentration-dependent inhibition of IL-4 - or IL-13-induced STAT6 activation, with IC50 values of 0.039 nM and 0.041 nM, respectively. In TF-1 cells, Stapokibart effectively inhibited IL-4 and IL-13-induced cell proliferation, with IC50 values of 1.75 nM and 0.13 nM, respectively. [1] |
| In vivo | In an OVA-induced asthma model, Stapokibart showed protective effects against IL-4/IL-13 induced airway inflammation in rats. Stapokibart (25, 50, 100 mg/kg) reduces disease severity of OVA-induced rhinitis in rats. [1] |
| Synonyms | CM310, CM 310 |
| Reactivity | Human |
| Verified Activity | Immobilized Human IL-4R alpha Protein (His) (TMPY-01055) at 1 μg/mL (100 μL/well) can bind Stapokibart. The EC50 is 25.19 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IL-4 R alpha/CD124 |
| Molecular Weight | 144.3 kDa |
| Cas No. | 2734715-10-5 |
| Isotype | Human IgG4SP kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Stapokibart chemical structure | Stapokibart in vivo | Stapokibart in vitro | Stapokibart molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.